0001193125-20-028147.txt : 20200207 0001193125-20-028147.hdr.sgml : 20200207 20200207160610 ACCESSION NUMBER: 0001193125-20-028147 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20200205 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20200207 DATE AS OF CHANGE: 20200207 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 20587420 BUSINESS ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-658-0600 MAIL ADDRESS: STREET 1: 85 WELLS AVENUE STREET 2: SECOND FLOOR CITY: NEWTON STATE: MA ZIP: 02459 8-K 1 d882920d8k.htm 8-K 8-K
false 0001503802 0001503802 2020-02-05 2020-02-05

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 5, 2020

 

Karyopharm Therapeutics Inc.

(Exact Name of Registrant as Specified in Charter)

 

Delaware

  

001-36167

  

26-3931704

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

85 Wells Avenue, 2nd Floor Newton, Massachusetts

  

02459

(Address of Principal Executive Offices)

  

(Zip Code)

Registrant’s telephone number, including area code: (617) 658-0600

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.0001 par value

  

KPTI

  

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Option and Restricted Stock Unit Grants

On February 5, 2020, the Board of Directors (the “Board”) of Karyopharm Therapeutics Inc. (the “Company”), upon recommendation of the Compensation Committee (the “Compensation Committee”), approved the following equity awards: (i) an option to purchase 153,500 shares of common stock, par value $0.0001 per share, of the Company (the “Common Stock”) and 57,200 restricted stock units (“RSUs”) to Michael Kauffman, M.D., Ph.D., Chief Executive Officer, (ii) an option to purchase 153,500 shares of Common Stock and 57,200 RSUs to Sharon Shacham, Ph.D., M.B.A., President and Chief Scientific Officer, (iii) an option to purchase 81,200 shares of Common Stock and 30,300 RSUs to Christopher B. Primiano, Executive Vice President, Chief Business Officer, General Counsel and Secretary, and (iv) an option to purchase 87,600 shares of Common Stock and 32,600 RSUs to Michael Mason, Senior Vice President, Chief Financial Officer and Treasurer. Each of the options and the RSUs were granted effective as of February 5, 2020 and made pursuant to the Company’s 2013 Stock Incentive Plan. The option exercise price is $18.00 per share, which is the fair market value per share on the date of grant and is equal to the closing price of the Common Stock on the Nasdaq Global Select Market on February 5, 2020. The options vest as to 25% of the shares underlying the option on the first anniversary of the date of grant, with the remainder vesting in equal increments over 36 additional months. Each RSU represents the right to receive one share of Common Stock upon vesting of the RSU. The RSUs vest as to 25% of the total number of RSUs on each of the first anniversary of the grant date and the three successive anniversaries of the grant date thereafter.

Other Compensation

On February 5, 2020, upon recommendation of the Compensation Committee, the Board approved for Drs. Kauffman and Shacham and Messrs. Primiano and Mason, performance-based bonus payments for 2019, and new annual base salaries for 2020, effective January 1, 2020, as set forth in the table below:

Name

 

2019
Bonus

   

2020
Annual
Salary

 

Michael G. Kauffman, M.D., Ph.D.

   

     

 

Chief Executive Officer

  $

363,693

    $

625,000

 

Sharon Shacham, Ph.D., M.B.A.

   

     

 

President and Chief Scientific Officer

  $

250,648

    $

483,000

 

Christopher B. Primiano

   

     

 

Executive Vice President, Chief Business Officer, General Counsel and Secretary

  $

175,979

    $

432,000

 

Michael Mason

   

     

 

Senior Vice President, Chief Financial Officer and Treasurer

  $

140,702

 *   $

415,000

 

* Amount prorated for the period from Mr. Mason’s date of hire (February 25, 2019) through December 31, 2019.

The Compensation Committee recommended, and the Board approved, the following target bonus amounts for 2020 for Drs. Kauffman and Shacham and Messrs. Primiano and Mason as a percentage of the annual base salaries for 2020: 60% for Dr. Kauffman, 50% for Dr. Shacham and 40% for Messrs. Primiano and Mason.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

KARYOPHARM THERAPEUTICS INC.

             

Date: February 7, 2020

 

 

By:

 

/s/ Christopher B. Primiano

 

 

 

Christopher B. Primiano

 

 

 

Executive Vice President, Chief Business Officer, General Counsel and Secretary

EX-101.SCH 2 kpti-20200205.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 kpti-20200205_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 kpti-20200205_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3.a.u2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d882920d8k.htm kpti-20200205.xsd kpti-20200205_lab.xml kpti-20200205_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 6 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d882920d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d882920d8k.htm" ] }, "labelLink": { "local": [ "kpti-20200205_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "kpti-20200205_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "kpti-20200205.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "kpti", "nsuri": "http://www.karyopharm.com/20200205", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d882920d8k.htm", "contextRef": "duration_2020-02-05_to_2020-02-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "body", "html" ], "baseRef": "d882920d8k.htm", "contextRef": "duration_2020-02-05_to_2020-02-05", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://www.karyopharm.com//20200205/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 R1.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Document and Entity Information
Feb. 05, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001503802
Document Type 8-K
Document Period End Date Feb. 05, 2020
Entity Registrant Name Karyopharm Therapeutics Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-36167
Entity Tax Identification Number 26-3931704
Entity Address, Address Line One 85 Wells Avenue
Entity Address, Address Line Two 2nd Floor
Entity Address, City or Town Newton
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02459
City Area Code (617)
Local Phone Number 658-0600
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.0001 par value
Trading Symbol KPTI
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
ZIP 10 0001193125-20-028147-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-028147-xbrl.zip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end XML 11 d882920d8k_htm.xml IDEA: XBRL DOCUMENT 0001503802 2020-02-05 2020-02-05 false 0001503802 8-K 2020-02-05 Karyopharm Therapeutics Inc. DE 001-36167 26-3931704 85 Wells Avenue 2nd Floor Newton MA 02459 (617) 658-0600 false false false false Common Stock, $0.0001 par value KPTI NASDAQ false XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; }